MetaCap

Repligen Statistics

NASDAQ: RGENHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

163.81-6.48 (-3.81%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Repligen by the numbers

Repligen has a market capitalization of $10.47 billion based on 63.92M shares outstanding. With trailing EPS of $-0.21, Repligen is unprofitable on a 12-month basis, so earnings-based valuation ratios do not apply. The stock trades 7.5% below its 50-day average and 12.4% above its 200-day average.

Average daily trading volume is 1.17M shares, or about $191.3 million in dollar volume.

Summary generated from market data by MetaCap's automated system. Methodology

RGEN valuation vs. peer median

RGEN compared with the median of 8 peer companies
MetricRGENPeer medianDifference
Market cap$10.47B$9.50B+10%
Forward P/E61.825.0+148%
Avg. volume1.17M2.23M-48%

Peer median across 8 companies: HALO, QGEN, KYMR, TECH, KRYS, PCVX, CGON, TWST.

Valuation

Market cap
$10.47B
Price / sales (latest FY)
14.18
EPS (TTM)
$-0.21

Price and trading

Previous close
170.29
Open
169.61
Day range
162.50 – 169.61
52-week range
100.99 – 198.87
52-week change
+0.80%
Beta
—
Volume
697.68K

Dividends and events

Annual dividend
None
Next earnings date
Oct 27, 2026

Additional statistics

Market Cap
10.47B
Forward Pe
61.77
Eps
-0.21
Dividend Yield
0.00%
Dividend Rate
0.00
Week52 High
198.87
Week52 Low
100.99
Avg Volume
1.17M
Shares Outstanding
63.92M
Ma50
177.16
Ma200
145.74
Earnings Date
Oct 27, 2026
Pct From52w High
-17.63%
Pct From52w Low
62.20%

Related